TORRANCE, Calif., April 15, 2024 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
